Acute decompensated heart failure (ADHF): A comprehensive contemporary review on preventing early readmissions and postdischarge death.

[1]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[2]  N. Sato,et al.  A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[3]  K. Bilchick,et al.  COST ANALYSIS OF HEART FAILURE READMISSION INTERVENTION PROGRAM , 2016 .

[4]  A. Strömberg,et al.  Do Self-Management Interventions Work in Patients With Heart Failure?: An Individual Patient Data Meta-Analysis , 2016, Circulation.

[5]  G. Moe.  Heart failure with multiple comorbidities , 2016, Current opinion in cardiology.

[6]  G. Guyatt,et al.  Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies , 2016, British Medical Journal.

[7]  G. Fonarow,et al.  Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure. , 2016, JACC. Heart failure.

[8]  L. Stevenson,et al.  Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial , 2016, The Lancet.

[9]  Wing W. Chan,et al.  Comparison of Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource Utilization in Patients With Heart Failure and Preserved Versus Reduced Ejection Fraction. , 2015, The American journal of cardiology.

[10]  A. Moss,et al.  Inverse Relationship of Blood Pressure to Long-Term Outcomes and Benefit of Cardiac Resynchronization Therapy in Patients With Mild Heart Failure: A Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Long-Term Follow-Up Substudy. , 2015, Circulation. Heart failure.

[11]  P. Kirchhof,et al.  Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data , 2015, BMJ : British Medical Journal.

[12]  S. Pocock,et al.  Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients , 2015, Current medical research and opinion.

[13]  V. Hasselblad,et al.  Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. , 2015, American heart journal.

[14]  K. Anstrom,et al.  Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). , 2015, Circulation. Heart failure.

[15]  David O. Martin,et al.  Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial. , 2015, JACC. Heart failure.

[16]  K. Anstrom,et al.  Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights from DOSE-AHF and CARRESS-HF , 2015 .

[17]  Deepak L. Bhatt,et al.  Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization , 2015, Journal of the American Heart Association.

[18]  D. Aronson,et al.  Interaction between worsening renal function and persistent congestion in acute decompensated heart failure. , 2015, The American journal of cardiology.

[19]  M. Pfisterer,et al.  Differential prognostic impact of resting heart rate in older compared with younger patients with chronic heart failure--insights from TIME-CHF. , 2015, Journal of cardiac failure.

[20]  C. Angermann,et al.  Nurse‐coordinated collaborative disease management improves the quality of guideline‐recommended heart failure therapy, patient‐reported outcomes, and left ventricular remodelling , 2015, European journal of heart failure.

[21]  S. Solomon,et al.  Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. , 2015, European heart journal.

[22]  F. Martinez,et al.  Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. , 2015, Journal of cardiac failure.

[23]  F. Zannad,et al.  Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure. , 2015, JACC. Heart failure.

[24]  M. de Antonio,et al.  Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. , 2015, Journal of the American College of Cardiology.

[25]  Harlan M Krumholz,et al.  Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study , 2015, BMJ : British Medical Journal.

[26]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.

[27]  K. Daly,et al.  Heart rate awareness in patients with chronic stable heart failure. A multi-center observational study. , 2014, International journal of cardiology.

[28]  Steven H. Landers,et al.  Mini-cog performance: novel marker of post discharge risk among patients hospitalized for heart failure. , 2014, Circulation. Heart failure.

[29]  Y. Pinto,et al.  Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study. , 2014, Journal of cardiac failure.

[30]  Akshay S. Desai,et al.  A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure , 2014, European heart journal.

[31]  William T. Abraham,et al.  Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction , 2014, Circulation. Heart failure.

[32]  C. Torp‐Pedersen,et al.  Effect of extended follow‐up in a specialized heart failure clinic on adherence to guideline recommended therapy: NorthStar Adherence Study , 2014, European journal of heart failure.

[33]  L. Maier,et al.  Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. , 2014, Biomarkers in medicine.

[34]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[35]  G. Curfman,et al.  Paradigm shifts in heart-failure therapy--a timeline. , 2014, The New England journal of medicine.

[36]  J. Butler,et al.  Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). , 2014, The American journal of cardiology.

[37]  P. Ponikowski,et al.  Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† , 2014, European heart journal.

[38]  F. S. Mendes,et al.  Atrial Fibrillation in Decompensated Heart Failure: Associated Factors and In-Hospital Outcome , 2014, Arquivos brasileiros de cardiologia.

[39]  Akshay S. Desai,et al.  Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction , 2014, Circulation. Heart failure.

[40]  R. McKelvie,et al.  Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I‐Preserve) , 2014, European journal of heart failure.

[41]  Anne L. Taylor,et al.  Effect of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine on All Hospitalizations and on 30-Day Readmission Rates in Patients With Heart Failure: Results From the African-American Heart Failure Trial , 2014, Circulation. Heart failure.

[42]  D. Kass,et al.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. , 2014, Circulation research.

[43]  John G F Cleland,et al.  Is heart rate important for patients with heart failure in atrial fibrillation? , 2014, JACC. Heart failure.

[44]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[45]  Naoki Sato,et al.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. , 2014, Journal of the American College of Cardiology.

[46]  G. Filippatos,et al.  Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. , 2014, International journal of cardiology.

[47]  H. Krum,et al.  Worsening renal function during renin–angiotensin–aldosterone system inhibitor initiation and long‐term outcomes in patients with left ventricular systolic dysfunction , 2014, European journal of heart failure.

[48]  Luigi Tavazzi,et al.  Co‐morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey , 2014, European journal of heart failure.

[49]  P. Erne,et al.  Long-Term Results of Intensified, N-Terminal-Pro-B-Type Natriuretic Peptide–Guided Versus Symptom-Guided Treatment in Elderly Patients With Heart Failure: Five-Year Follow-Up From TIME-CHF , 2013, Circulation. Heart failure.

[50]  P. Ponikowski,et al.  Heart Failure in Patients With Atrial Fibrillation Is Associated With a High Symptom and Hospitalization Burden: The RealiseAF Survey , 2013, Clinical cardiology.

[51]  K. Swedberg,et al.  Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial , 2013, European journal of heart failure.

[52]  P. Ponikowski,et al.  Predictors of Post-Discharge Outcomes from Information Acquired Shortly After Admission for Acute Heart Failure: A Report from the PROTECT Study , 2013 .

[53]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[54]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[55]  J. Fleg,et al.  Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. , 2013, The American journal of medicine.

[56]  G. Filippatos,et al.  Effect of oral digoxin in high‐risk heart failure patients: a pre‐specified subgroup analysis of the DIG trial , 2013, European journal of heart failure.

[57]  L. Tavazzi,et al.  Multicenter Prospective Observational Study on Acute and Chronic Heart FailureClinical Perspective , 2013 .

[58]  G. Jondeau,et al.  Current aspects of the spectrum of acute heart failure syndromes in a real‐life setting: the OFICA study , 2013, European journal of heart failure.

[59]  Akshay S. Desai,et al.  Treatment of anemia with darbepoetin alfa in systolic heart failure. , 2013, The New England journal of medicine.

[60]  K. Swedberg,et al.  Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. , 2013, European heart journal.

[61]  I. V. Van Gelder,et al.  Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. , 2013, JACC. Heart failure.

[62]  Leora I. Horwitz,et al.  Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. , 2013, JAMA.

[63]  K. Anstrom,et al.  Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.

[64]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[65]  K. Swedberg,et al.  Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study , 2012, European heart journal.

[66]  Akshay S. Desai,et al.  Rehospitalization for heart failure: predict or prevent? , 2012, Circulation.

[67]  Peter C Austin,et al.  Lifetime Analysis of Hospitalizations and Survival of Patients Newly Admitted With Heart Failure , 2012, Circulation. Heart failure.

[68]  K. Swedberg,et al.  Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. , 2012, Journal of the American College of Cardiology.

[69]  D. Kaye,et al.  Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction. , 2012, International journal of cardiology.

[70]  S. Thomas,et al.  Hemodynamic classifications of acute heart failure and their clinical application: – an update –. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[71]  M. Metra,et al.  Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure?: The Role of Congestion and Its Interaction With Renal Function , 2012, Circulation. Heart failure.

[72]  Adrian F Hernandez,et al.  Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[73]  M. Prins,et al.  Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. , 2010, Journal of the American College of Cardiology.

[74]  W. Gibler,et al.  Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. , 2010, Circulation.

[75]  Inger Ekman,et al.  Population Impact of Heart Failure and the Most Common Forms of Cancer: A Study of 1 162 309 Hospital Cases in Sweden (1988 to 2004) , 2010, Circulation. Cardiovascular quality and outcomes.

[76]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[77]  Michael Böhm,et al.  Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial , 2010, The Lancet.

[78]  M. Zile,et al.  Chronic Ambulatory Intracardiac Pressures and Future Heart Failure Events , 2010, Circulation. Heart failure.

[79]  C. O'connor,et al.  Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. , 2010, American heart journal.

[80]  P. Sobotka,et al.  Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. , 2010, Journal of cardiac failure.

[81]  C. Belziti,et al.  Worsening renal function in patients admitted with acute decompensated heart failure: incidence, risk factors and prognostic implications. , 2010, Revista espanola de cardiologia.

[82]  C. Belziti,et al.  Empeoramiento de la función renal en pacientes hospitalizados por insuficiencia cardiaca aguda descompensada: incidencia, predictores y valor pronóstico , 2010 .

[83]  P. Ponikowski,et al.  Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative , 2009, European heart journal.

[84]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[85]  C. Yancy,et al.  Characteristics and in-hospital outcomes for nonadherent patients with heart failure: findings from Get With The Guidelines-Heart Failure (GWTG-HF). , 2009, American heart journal.

[86]  G. Fonarow,et al.  Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. , 2009, American heart journal.

[87]  S. Goldhaber,et al.  Pulmonary embolism in heart failure. , 2008, Circulation.

[88]  M. Zile,et al.  Transition From Chronic Compensated to Acute Decompensated Heart Failure: Pathophysiological Insights Obtained From Continuous Monitoring of Intracardiac Pressures , 2008, Circulation.

[89]  D. Lai,et al.  Decreasing body temperature predicts early rehospitalization in congestive heart failure. , 2008, Journal of cardiac failure.

[90]  H. Yagi,et al.  Decreased renal function as an independent predictor of re-hospitalization for congestive heart failure. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[91]  J. R. Banegas,et al.  El autocuidado y el conocimiento del manejo de la enfermedad predicen la rehospitalización en ancianos con insuficiencia cardíaca , 2008 .

[92]  C. O'connor,et al.  Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. , 2008, Archives of internal medicine.

[93]  John G F Cleland,et al.  Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. , 2007, Journal of cardiac failure.

[94]  P. Poole‐Wilson,et al.  Should beta‐blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET , 2007, European journal of heart failure.

[95]  A. Hoes,et al.  Clinical epidemiology of heart failure , 2007, Heart.

[96]  G. Fonarow,et al.  Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. , 2007, European heart journal.

[97]  G. Filippatos,et al.  Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. , 2006, The American journal of medicine.

[98]  W. Maisel,et al.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy , 2003 .

[99]  D. Grobbee,et al.  Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. , 2002, Archives of internal medicine.

[100]  S Capewell,et al.  More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failure , 2001, European journal of heart failure.

[101]  T. Uejima,et al.  Incidence and predictors of rehospitalization of acute heart failure patients. , 2015, International heart journal.

[102]  Steven H. Landers,et al.  Mini-Cog PerformanceCLINICAL PERSPECTIVE , 2015 .

[103]  A. Santoro,et al.  Continuous ultrafiltration for congestive heart failure: the CUORE trial. , 2014, Journal of cardiac failure.

[104]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[105]  L. Tavazzi,et al.  Multicenter Prospective Observational Study on Acute and Chronic Heart Failure One-Year Follow-up Results of IN-HF ( Italian Network on Heart Failure ) Outcome Registry , 2022 .